Jade Biosciences
JBIO
55 hedge funds and large institutions have $447M invested in Jade Biosciences in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more funds holding
Funds holding: 49 → 55 (+6)
11% more capital invested
Capital invested by funds: $403M → $447M (+$44.4M)
0.14% more ownership
Funds ownership: 3.02% → 3.15% (+0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 2 |
O
OrbiMed
New York
|
+$6.03M |
| 3 |
VA
VR Adviser
New York
|
+$4.64M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.81M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$5.92M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.06M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.09M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.73M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$381K |
JBIO Hedge Fund Activity: Q3 2022 in Review
55 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q3 2022, worth a combined $447M — up 11% from $403M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new JBIO positions and 4 closed out — a net gain of 6 holders — while 20 added to existing stakes and 17 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $11.4M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $5.92M.
- 55 institutional investors held Jade Biosciences (JBIO) as of Q3 2022, up from 49 in Q2 2022.
- Funds reported $447M of Jade Biosciences stock for Q3 2022, up 11% quarter-over-quarter.
- 10 funds opened new Jade Biosciences positions in Q3 2022 and 4 closed out, a net change of +6 holders.
- The largest Jade Biosciences buyer in Q3 2022 was Cormorant Asset Management, an estimated $11.4M added.
- The largest Jade Biosciences seller in Q3 2022 was Atlas Venture Life Science Advisors, an estimated $5.92M sold.
Based on aggregated 13F filings for Q3 2022.